



María Angel García Chaves

Generated from: Editor CVN de FECYT

Date of document: 06/10/2022

v 1.4.3

1c38ecd2b4662b92d6246b10aff04e5a

This electronic file (PDF) has embedded CVN technology (CVN-XML). The CVN technology of this file allows you to export and import curricular data from and to any compatible data base. List of adapted databases available at: <http://cvn.fecyt.es/>



General quality indicators of scientific research

This section describes briefly the main quality indicators of scientific production (periods of research activity, experience in supervising doctoral theses, total citations, articles in journals of the first quartile, H index...). It also includes other important aspects or peculiarities.

Indice H 24 (scopus) Citas: 2278 (scopus); Indice H 26 (Google Académico) Citas: 3460 (Google Académico)

3 Sexenios de Investigación reconocidos por la ANECA

4 Quinquenios docentes reconocidos por la UGR

5 Trienios reconocidos por la UGR



María Angel García Chaves

Surname(s): **García Chaves**
 Name: **María Angel**
 ORCID: **0000-0003-2003-3769**
 ScopusID: **35214887900**
 Gender: **Female**
 Nationality: **Spain**
 Country of birth: **Spain**
 City of birth: **Granada**
 Contact country: **Spain**
 Contact city: **Granada**
 Land line phone: **958243524 - 43524**
 Email: **mangelgarcia@ugr.es**

Current professional situation

Employing entity: Universidad de Granada **Type of entity:** University
Department: Bioquímica y Biología Molecular III e Inmunología, Facultad de Medicina
Professional category: Profesora Titular de Universidad
Start date: 31/07/2020
Type of contract: Civil servant **Dedication regime:** Full time
Performed tasks: Docencia e Investigación

Previous positions and activities

	Employing entity	Professional category	Start date
1	Universidad de Granada	Profesora Ayudante Doctora	01/02/2019
2	Sistema Andaluz de Salud, SAS	Investigadora programa Nicolás Monardes	09/11/2018
3	Universidad de Granada	Profesora Sustituta Interina	01/10/2017
4	Instituto de Salud Carlos III/Fundación FIBAO	Contratada Programa Miguel Servet tipo I y II	16/02/2009
5	Consejo Superior de Investigaciones Científicas	Contrato para doctores I3P	01/01/2007
6	Fundación Marcelino Botín	Contratado Doctor	01/08/2005
7	Consejo Superior de Investigaciones Científicas	Beca Posdoctoral	01/05/2004
8	MINISTERIO DE EDUCACION Y CIENCIA	Beca predoctoral FPI	01/07/2000
9	Consejo Superior de Investigaciones Científicas	Beca predoctoral	01/07/1999

1 **Employing entity:** Universidad de Granada **Type of entity:** University
Professional category: Profesora Ayudante Doctora
Start-End date: 01/02/2019 - 28/02/2019



- 2** **Employing entity:** Sistema Andaluz de Salud, SAS
Professional category: Investigadora programa Nicolás Monardes
Start-End date: 09/11/2018 - 31/01/2019
- 3** **Employing entity:** Universidad de Granada **Type of entity:** University
Professional category: Profesora Sustituta Interina
Start-End date: 01/10/2017 - 05/11/2018
- 4** **Employing entity:** Instituto de Salud Carlos III/Fundación FIBAO **Type of entity:** Public Research Body
Professional category: Contratada Programa Miguel Servet tipo I y II
Start-End date: 16/02/2009 - 30/09/2017 **Duration:** 3 years
- 5** **Employing entity:** Consejo Superior de Investigaciones Científicas **Type of entity:** State agency
Professional category: Contrato para doctores I3P
Start-End date: 01/01/2007 - 15/02/2009 **Duration:** 2 years - 1 month - 15 days
- 6** **Employing entity:** Fundación Marcelino Botín **Type of entity:** Foundation
Professional category: Contratado Doctor
Start-End date: 01/08/2005 - 31/12/2006 **Duration:** 1 year - 5 months
- 7** **Employing entity:** Consejo Superior de Investigaciones Científicas **Type of entity:** State agency
Professional category: Beca Posdoctoral
Start-End date: 01/05/2004 - 31/07/2005
- 8** **Employing entity:** MINISTERIO DE EDUCACION Y CIENCIA
Professional category: Beca predoctoral FPI
Start-End date: 01/07/2000 - 30/04/2004
- 9** **Employing entity:** Consejo Superior de Investigaciones Científicas **Type of entity:** State agency
Professional category: Beca predoctoral
Start-End date: 01/07/1999 - 30/06/2000



Education

University education

1st and 2nd cycle studies and pre-Bologna degrees

University degree: Higher degree

Name of qualification: Licenciado en Biología

Degree awarding entity: Universidad de Granada **Type of entity:** University

Date of qualification: 06/09/1997

Doctorates

1 **Doctorate programme:** Master propio en fabricacion de medicamentos de terapias avanzadas, especialidad en direccion tecnica

Degree awarding entity: Universidad de Granada/IATA **Type of entity:** University

Date of degree: 01/07/2011

2 **Doctorate programme:** Premio Extraordinario de Tesis

Degree awarding entity: Universidad Autónoma de Madrid **Type of entity:** University

Date of degree: 13/04/2005

3 **Doctorate programme:** Programa Oficial de Doctorado en Biología Molecular y Celular

Degree awarding entity: Universidad Autónoma de Madrid **Type of entity:** University

Date of degree: 30/04/2004

4 **Doctorate programme:** Tesis doctoral

Degree awarding entity: Universidad Autónoma de Madrid **Type of entity:** University

Date of degree: 30/04/2004

Language skills

Language	Listening skills	Reading skills	Spoken interaction	Speaking skills	Writing skills
English	B2	B2	B2	B2	B2



Teaching experience

Experience supervising doctoral thesis and/or final year projects

- 1 Project title:** Tesis de Máster dirigida: Eficiencia De Las Nanopartículas Interferida Por Distintas Barreras Biológicas
Entity: ibs.GRANADA
Student: Victor Amezcua
Date of reading: 12/09/2016
- 2 Project title:** Tesis de Master dirigida: One more step to understand the effect of Interferon- γ over Recurrence Free Survival in melanoma
Entity: Universidad de Granada
Student: Silvia Cobertera Pintor
Date of reading: 14/07/2016
Type of entity: University
- 3 Project title:** Tesis doctoral dirigida: ENRIQUECIMIENTO DE SUBPOBLACIONES DE CELULAS MADRE CANCERIGENAS EN BASE A SU CAPACIDAD DE ADHESION Y ESTUDIO DE MICRORNAs ESPECIFICOS: DESARROLLO DE TERAPIAS SELECTIVAS MEDIANTE FARMACOS Y NANOPARTICULAS
Entity: Universidad de Granada
Student: CYNTHIA MORATA TARIFA
Date of reading: 06/04/2015
Type of entity: University
- 4 Project title:** Tesis doctoral dirigida: DIFERENCIACION DE CELULAS MADRE COMO MODELO EXPERIMENTAL DE TERAPIA EN ENFERMEDADES PREVALENTES: OSTEOARTRITIS Y PATOLOGIA CARDIOVASCULAR
Entity: Universidad de Jaén
Student: Elena López Ruiz
Date of reading: 21/02/2014
Type of entity: University
- 5 Project title:** Tesis de máster dirigida: MARCADORES MOLECULARES IMPLICADOS EN LA RESPUESTA CELULAR AL 5-FLUOROURACILO
Entity: Universidad de Granada
Student: Gema Jiménez González
Date of reading: 01/10/2011
Type of entity: University
- 6 Project title:** Tesis de máster dirigida: EFECTO DEL SILENCIAMIENTO DE LA PROTEINA PKR EN LINEAS CELULARES TUMORALES DE COLON Y MAMA
Entity: Universidad de Granada
Student: Liliana Marcela Montilla Rodríguez
Date of reading: 01/10/2010
Type of entity: University
- 7 Project title:** Tesis de máster dirigida: MOLECULAR TARGETS OF INTERFERON ALFA AND 5-FLUOROURACIL COMBINED THERAPY IN COLON AND BREAST CANCER
Entity: Universidad de Granada
Student: Esther Carrasco Pardo
Date of reading: 01/10/2009
Type of entity: University



Healthcare experience

Other activities/achievements not included above

Other relevant activities: Premio de la Real Academia Nacional de Farmacia

Entity where project took place: Complejo Hospitalario de Granada **Type of entity:** Healthcare Institutions

End date: 2016

Scientific and technological experience

Scientific or technological activities

R&D projects funded through competitive calls of public or private entities

- 1 Name of the project:** Papel de la estrona, y de enzimas HSD17B implicadas en su síntesis, en el riesgo y progresión del cáncer de mama ER+ asociado a la obesidad y postmenopausia
Entity where project took place: Universidad de Granada **Type of entity:** State agency
Name of the programme: «Proyectos I+D+i» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»
Code according to the funding entity: PID2020-119502RJ-I00
Start-End date: 01/12/2021 - 12/12/2024 **Duration:** 3 years
- 2 Name of the project:** Plataforma ultrasensible basada en grafeno para el diagnóstico precoz del cáncer (Alerta)
Entity where project took place: Universidad de Granada
City of entity: Granada,
Funding entity or bodies: Instituto de Salud Carlos III **Type of entity:** Public Research Body
Start-End date: 01/01/2021 - 31/12/2023
- 3 Name of the project:** Nanoapatitos luminiscentes cargados con la toxina LdrB como herramienta terapéutica dirigida frente a células madre cancerígenas **ACRÓNIMO:** ToxApatStem
Entity where project took place: Universidad de Granada **Type of entity:** University
Funding entity or bodies: Universidad de Granada **Type of entity:** University
Start-End date: 01/07/2021 - 01/07/2023
- 4 Name of the project:** Bioimpresión 3D de microambientes tumorales ¿on-a-chip¿ con aplicación en medicina de precisión del cáncer
Entity where project took place: Universidad de Granada **Type of entity:** University

**Funding entity or bodies:**

Junta de Andalucía

Type of entity: P18-FR-2470**Start-End date:** 01/01/2020 - 31/12/2022**Total amount:** 155.625 €

- 5 Name of the project:** Biosensores basados en semiconductores bidimensionales para diagnóstico precoz del melanoma maligno

Entity where project took place: Universidad de Granada **Type of entity:** University**Start-End date:** 01/01/2020 - 31/12/2022**Total amount:** 116.042 €

- 6 Name of the project:** Mecanotransducción Mediante Ultrasonidos para la Mejora del Tratamiento del Cáncer

Entity where project took place: Instituto de Investigación Biomedimédica ibs.GRANADA**Funding entity or bodies:**

Instituto de Salud Carlos III, Acción Estratégica en Salud 2017, Proyectos de Desarrollo Tecnológico en Salud

Start-End date: 01/01/2018 - 31/12/2019**Total amount:** 54.450 €

- 7 Name of the project:** Implementation of a novel integrated platform to monitor tumour heterogeneity as a crucial determinant for individualized diagnostic and therapeutic outcome

Entity where project took place: Instituto de Investigación Biosanitaria ibs.GRANADA**City of entity:** Granada,**Name principal investigator (PI, Co-PI...):** Juan Antonio Marchal Corrales**Nº of researchers:** 36**Start-End date:** 01/01/2017 - 31/12/2019**Total amount:** 495.000 €

- 8 Name of the project:** Toxina Hokd como Nueva Herramienta Terapéutica Frente a Células Madre Cancerígenas Derivadas de Pacientes con Cáncer de Útero

Entity where project took place: Instituto de investigación Biomédica ibs.GRANADA**Funding entity or bodies:**

Fundación Mutua Madrileña

Start-End date: 01/01/2017 - 31/12/2019**Total amount:** 115.900 €

- 9 Name of the project:** Modelo Terapéutico de Regeneración Vasculare: uso de Arterias Descelularizadas recubiertas de Nuevos Polímeros y Ligandos Quiméricos que Favorecen la Reendotelización

Entity where project took place: Universidad de Jaén/Universidad de Granada**Funding entity or bodies:**

Consejería de Salud de la Junta de Andalucía, Proyectos de Innovación en Salud 2016

Start-End date: 01/01/2017 - 31/12/2018**Total amount:** 295.000 €

- 10 Name of the project:** Estudio prospectivo de validación de biomarcadores de respuesta a quimioterapia y terapias biológicas en pacientes con cáncer colorrectal metastásico

Type of project: Research and development, including transfer**Type of entity:** University Research Institute



Entity where project took place: Complejo Hospitalario Universitario de Granada

City of entity: Granada, Andalusia, Spain

Name principal investigator (PI, Co-PI....): María Angel Garcia Chaves

Nº of researchers: 8

Funding entity or bodies:

Instituto de Salud Carlos III

Type of entity: Public Research Body

City funding entity: Majadahonda, Community of Madrid, Spain

Start-End date: 01/01/2016 - 31/12/2017

Total amount: 67.100 €

11 Name of the project: Valor Predictivo de la Quinasa PKR y Sus Reguladores en Pacientes Con Cáncer de Colon Metastásico

Entity where project took place: Complejo Hospitalario Universitario de Granada

Type of entity: Healthcare Institutions

City of entity: Granada, Andalusia, Spain

Name principal investigator (PI, Co-PI....): María Angel García Chaves Chaves

Nº of researchers: 7

Funding entity or bodies:

Consejería de Salud de la Junta de Andalucía

Type of entity: Entidad pública

City funding entity: Sevilla, Andalusia, Spain

Start-End date: 01/09/2015 - 30/09/2017

Total amount: 33.900 €

12 Name of the project: Método y medio de aislamiento y enriquecimiento de células madre cancerígenas con utilidad diagnóstica y terapéutica en oncología

Entity where project took place: Instituto de Investigación Biosanitaria de Granada

Type of entity: Healthcare Institutions

City of entity: Granada, Andalusia, Spain

Name principal investigator (PI, Co-PI....): María Angel García Chaves

Nº of researchers: 4

Funding entity or bodies:

Fundación para la Innovación y la Prospectiva en Salud en España, FIPSE

Type of entity: Healthcare Institutions

City funding entity: Madrid, Community of Madrid, Spain

Start-End date: 01/01/2016 - 30/03/2017

Total amount: 25.000 €

13 Name of the project: BIOMER CONDROSTEM 3-D: biomedicina regenerativa de patologia condral mediante el uso de celulas madre autologas

Entity where project took place: Universidad de Granada/Hospital Virgen de las Nieves

City of entity: Granada, Andalusia, Spain

Name principal investigator (PI, Co-PI....): Juan Antonio Marchal Corrales

Nº of researchers: 10

Funding entity or bodies:

Consejería de Salud de la Junta de Andalucía

Type of entity: Proyecto Excelencia

City funding entity: Sevilla, Andalusia, Spain

Start-End date: 01/01/2011 - 05/07/2015

Total amount: 210.000 €



- 14 Name of the project:** Estudio del mecanismo de acción y actividad antitumoral in vivo de un compuesto obtenido a partir de extractos naturales frente a células madre pancreáticas
Entity where project took place: Universidad de Granada/Fundación Medina
City of entity: Granada, Andalucía, Spain
Name principal investigator (PI, Co-PI....): Juan Antonio Marchal Corrales
Nº of researchers: 7
Funding entity or bodies:
CeIBiotic Campus de Excelencia **Type of entity:** University
City funding entity: Granada, Andalucía, Spain
Start-End date: 01/06/2014 - 01/06/2015
Total amount: 21.500 €
- 15 Name of the project:** Efectividad mediada por núcleos benzoheteroepínicos e interferón como terapia antitumoral en células tumorales y cáncer stem cells procedentes de tumores de mama y colon
Entity where project took place: Hospital **Type of entity:** Healthcare Institutions
Universitario Virgen de las Nieves
City of entity: Granada, Andalucía, Spain
Name principal investigator (PI, Co-PI....): María Angel García Chaves
Nº of researchers: 1
Funding entity or bodies:
Instituto de Salud Carlos III **Type of entity:** Public Research Body
City funding entity: Majadahonda, Community of Madrid, Spain
Start-End date: 16/02/2009 - 16/02/2012
Total amount: 45.000 €
Applicant's contribution: Proyecto Miguel Servet
- 16 Name of the project:** PAPEL DE LAS CELULAS MADRE CANCERIGENAS DE TUMORES DE MAMA, COLON Y MELANOMA EN LA RESPUESTA A LA TERAPIA ANTITUMORAL: CARACTERIZACION Y ACTIVIDAD SELECTIVA DE NUEVAS BASES HETEROCICLICAS
Entity where project took place: Universidad de Granada/Hospital Virgen de las Nieves
City of entity: Granada, Andalucía, Spain
Name principal investigator (PI, Co-PI....): Juan Antonio Marchal Corrales
Nº of researchers: 16
Funding entity or bodies:
CENTRO DE ACUSTICA APLICADA Y **Type of entity:** Associations and Groups
EVALUACION NO DESTRUCTIVA
Instituto de Salud Carlos III **Type of entity:** Public Research Body
City funding entity: Majadahonda, Community of Madrid, Spain
Start-End date: 01/01/2011 - 01/01/2012
Total amount: 119.185 €
Applicant's contribution: Baja cursada para poder concurrir en nuevas convocatorias como IP
- 17 Name of the project:** CARACTERIZACION Y PAPEL DE LAS CELULAS MADRE CANCERIGENAS DE TUMORES COLORRECTALES EN LA RESPUESTA A LA TERAPIA ANTITUMORAL
Entity where project took place: Universidad de Granada/Hospital Virgen de las Nieves
City of entity: Granada, Andalucía, Spain
Name principal investigator (PI, Co-PI....): Juan Antonio Marchal Corrales
Nº of researchers: 7
Funding entity or bodies:
CeIBiotic Campus de Excelencia



City funding entity: Granada, Andalusia, Spain

Start-End date: 07/04/2011 - 31/12/2011

Total amount: 10.000 €

18 Name of the project: CARACTERIZACION FUNCIONAL Y UTILIZACION DE LA PROTEINA KINASA (PKR) INDUCIDA POR LOS INTERFERONES COMO MEDIADOR DE APOPTOSIS E INHIBIDOR TUMORAL

Entity where project took place: Centro Nacional de Biotecnología/CSIC

City of entity: Madrid, Community of Madrid, Spain

Name principal investigator (PI, Co-PI...): Mariano Esteban Rodriguez

Nº of researchers: 4

Funding entity or bodies:

Ministerio de Ciencia e Innovación. Investigación **Type of entity:** Ministerio

City funding entity: Madrid, Community of Madrid, Spain

Start-End date: 31/12/2005 - 31/12/2008

19 Name of the project: Mecanismo de Acción de los Interferones: Análisis Estructural y Funcional de la Proteína Quinasa PKR, un Activador de Apoptosis e Inhibidor Viral

Entity where project took place: Centro Nacional de Biotecnología/CSIC

Funding entity or bodies:

Ministerio de Educación y Ciencia

Start-End date: 01/01/2003 - 31/12/2004

Total amount: 196.650 €

R&D non-competitive contracts, agreements or projects with public or private entities

1 Name of the project: A novel formulation of pancreatic proenzymes provides potent antitumor efficacy: a pilot focused on pancreatic and ovarian cancer

Funding entity or bodies:

Propanc PTY LTD./Universidad de Jaén

Start date: 02/04/2017

Total amount: 7.025 €

2 Name of the project: Caracterización in vitro e in vivo de moléculas antitumorales en particular sobre rutas activas en cáncer stem cells (CSC) en el marco del proyecto FRIDASTEM

Entity where project took place: CANVAX BIOTECH, S.L.

Degree of contribution: Researcher

Entity where project took place: CANVAX BIOTECH, S.L.

Nº of researchers: 6

Funding entity or bodies:

CANVAX BIOTECH, S.L.

City funding entity: Spain

Start date: 01/09/2016

Duration: 1 year - 3 months

Total amount: 110.000 €

3 Name of the project: Biological Study of the antitumor activity of PRP

Degree of contribution: Coordinator of total project, network or consortium

Name principal investigator (PI, Co-PI...): Macarena Peran Quesada



Nº of researchers: 5

Participating entity/entities: FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO

Funding entity or bodies:

Propanc Health Group Corporation

Start date: 10/01/2016

Duration: 1 year - 6 months

Total amount: 59.400 €

4 Name of the project: In vivo study of the antitumor activity of PRP against CSCs

Degree of contribution: Coordinator of total project, network or consortium

Name principal investigator (PI, Co-PI....): Macarena Peran Quesada

Nº of researchers: 6

Participating entity/entities: FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO

Funding entity or bodies:

Propanc Health Group Corporation

Type of entity: Business

City funding entity: Victoria, Australia

Start date: 02/12/2015

Duration: 1 year - 6 months

Total amount: 50.050 €

5 Name of the project: Determination of gene expression by microarray analyses after treatment with Propanc formulations. Cell differentiation assays

Name principal investigator (PI, Co-PI....): Macarena Peran Quesada

Nº of researchers: 6

Funding entity or bodies:

Propanc Health Group Corporation

City funding entity: Canada

Start date: 02/04/2015

Duration: 6 months

Total amount: 29.400 €

Results

Industrial and intellectual property

1 Title registered industrial property: Método de obtención de datos útiles para predecir o pronosticar la supervivencia global y la supervivencia libre de recaídas en el cáncer y composición capaz de modular la actividad de ATF4 para el tratamiento del cáncer

Entity holder of rights: Sistema Andaluz de Salud/UGR

Nº of application: WO/2020/008097

Date of register: 03/07/2019

Conferral date: 09/01/2020

2 Title registered industrial property: Composición capaz de modular la actividad de ATF4 para el tratamiento del cáncer

Inventors/authors/obtainers: Granados Principal Sergio Sánchez Rovira Pedro R

Entity holder of rights: Sistema Andaluz de Salud/UGR

Nº of application: P201830665

Date of register: 03/07/2018



- 3** **Title registered industrial property:** Método de obtención de datos útiles para predecir o pronosticar la supervivencia global y la supervivencia libre de recaídas en el cáncer
Entity holder of rights: Sistema Andaluz de Salud/UGR
Nº of application: P201830666
Date of register: 03/07/2018
- 4** **Title registered industrial property:** Medio de cultivo y método de enriquecimiento y mantenimiento de células troncales tumorales (CSCs) mediante el uso de dicho medio
Inventors/authors/obtainers: Juan Antonio Marchal; Gema Jimenez; Cynthia Morata; María Angel García; Macarena Perán
Entity holder of rights: Universidad de Granada
Nº of application: WO 2016/020572 A1
Country of inscription: Spain, Andalusia
Date of register: 04/08/2014
Conferral date: 02/11/2016
- 5** **Title registered industrial property:** Método de obtención de datos útiles para evaluar, predecir y/o pronosticar la respuesta al tratamiento con análogos de pirimidina
Inventors/authors/obtainers: María Angel García; Margarita Aguilera; Miguel Angel Calleja; Juan Antonio Marchal; Mariano Esteban; Esther Carrasco; Gema Jimenez; Antonia Aránega
Entity holder of rights: Sistema Andaluz de Salud
Nº of application: WO2012113965
Country of inscription: Spain, Andalusia
Date of register: 24/02/2011
Conferral date: 30/08/2012
- 6** **Title registered industrial property:** Enantiomeros de derivados benzoheteroepinicos y su uso como agentes antitumorales
Inventors/authors/obtainers: Duane Choquesillo; Juan Antonio Marchal; Antonia Aranega; Ana Conejo; María Angel García; Olga Cruz; Houria Boulaiz; Fernando Rodriguez; Carlos Cativiela; Macarena Peran; Ana Isabel Jimenez; Juan Manuel García; Joaquin Campos
Entity holder of rights: Servicio Andaluz de Salud
Nº of application: WO 2011/117449 A1
Date of register: 22/03/2010
Conferral date: 29/09/2011



Scientific and technological activities

Scientific production

- 1** **H index:** 27
Date of application: 05/10/2022
Fuente de Índice H: GOOGLE SCHOLAR
- 2** **H index:** 24
Date of application: 05/10/2022
Fuente de Índice H: SCOPUS

Publications, scientific and technical documents

- 1** Caffeine and Chlorogenic Acid Combination Attenuate Early-Stage Chemically Induced Colon Carcinogenesis in Mice: Involvement of oncomiR miR-21a-5p. 2022.
Type of production: Scientific paper
Corresponding author: Yes
- 2** Jose Luis Palacios-Ferrer; Maria Belen Garcia-Ortega; Maria Gallardo-Gomez; Maria Angel Garcia; Houria Boulaiz; Javier Valdivia; Caridad Diaz. Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma. *Molecular Oncology*. 15 - 2, pp. 407 - 428. 14/10/2020.
Type of production: Scientific paper
Format: Journal
Position of signature: 4
Total no. authors: 15
- 3** María Belén Ortega García; Alberto Mesa; Elisa L J Moya; Beatriz Rueda; Gabriel Lopez Ordoño; Javier Ángel García; Verónica Conde; Eduardo Redondo Cerezo; Javier Luis Lopez Hidalgo; Gema Jiménez; Macarena Peran; Luis J Martínez González; Coral Del Val; Igor Zwir; Juan Antonio Marchal; María Ángel García. Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy. *Cancers*. 12 - 2, (Switzerland): 07/02/2020. ISSN 2072-6694
Type of production: Scientific paper
Format: Journal
Position of signature: 16
Total no. authors: 16
Corresponding author: Yes
- 4** Jiménez Martínez Yaiza; Ruiz Alcalá Gloria; García Ortega María Belén; López-Ruiz Elena; Jiménez Gema; Marchal Juan Antonio; García Chaves María Ángel; Boulaiz Houria. Melanoma cancer stem-like cells: Optimization method for culture, enrichment and maintenance. *Tissue & cell*. 60, pp. 48 - 59. 10/2019. ISSN 1532-3072
DOI: 10.1016/j.tice.2019.07.005
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 8
Corresponding author: Yes
- 5** Pablo Hernández Camarero; Elena López Ruiz; Carmen Griñán Lisón; María Ángel García; Carlos Chocarro Wrona; Juan Antonio Marchal; Julian Kenyon; Macarena Perán. Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting. *Scientific reports*. 9 - 1, pp. 11359. 06/08/2019. ISSN 2045-2322
DOI: 10.1038/s41598-019-47837-7



Type of production: Scientific paper
Position of signature: 4
Total no. authors: 8

- 6** González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Chang JC; García MA; Granados-Principal S; Qian W. Activating Transcription Factor 4 Modulates TGF β -Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. *Cancer Research*. 24 - 22, pp. 5697 - 5709. 2018.
DOI: 10.1158/1078-0432.CCR-17-3125
Type of production: Scientific paper **Format:** Journal
Position of signature: 11
Total no. authors: 13
- 7** Jiménez G; Hackenberg M; Catalina P; Boulaiz H; Griñán-Lisón C; García MA; Perán M; López-Ruiz E; Ramírez A; Morata-Tarifa C; Carrasco E; Aguilera M; Marchal JA. Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile. *Cancer Lett*. 429, pp. 78 - 88. 2018.
DOI: 10.1016/j.canlet.2018.04.042
Type of production: Scientific paper **Format:** Journal
Position of signature: 6
Total no. authors: 13
- 8** C Morata Tarifa; M Picon Ruiz; C Griñan Lison; H Boulaiz; M Perán; M A Garcia; J A Marchal. Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity. *Scientific reports*. 7, pp. 39782. 04/01/2017. ISSN 2045-2322
DOI: 10.1038/srep39782
Type of production: Scientific paper **Format:** Journal
Position of signature: 6
Total no. authors: 7 **Corresponding author:** Yes
- 9** Cruz-López O; Ramírez A; Navarro SA; García MA; Marchal JA; Campos JM; Conejo-García A. 1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds. *Future Med Chem*. 9 - 11, pp. 1129 - 1140. 2017.
DOI: 10.4155/fmc-2017-0006
Type of production: Scientific paper **Format:** Journal
Position of signature: 4
Total no. authors: 7
- 10** Perán M; López-Ruiz E; García MA; Nadaraia-Hoke S; Brandt R; Marchal JA; Kenyon J. A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: A pilot study focused on pancreatic and ovarian cancer. *Scientific Reports*. 7 - 1, pp. 13998. 2017.
DOI: 10.1038/s41598-017-14571-x
Type of production: Scientific paper **Format:** Journal
Position of signature: 3
Total no. authors: 7
- 11** Cynthia Morata Tarifa; Gema Jiménez; María A García; José M Entrena; Carmen Griñán Lisón; Margarita Aguilera; Manuel Picon Ruiz; Juan A Marchal. Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells. *Scientific reports*. 6, pp. 18772. 2016. ISSN 2045-2322
DOI: 10.1038/srep18772
Type of production: Scientific paper **Format:** Journal
Position of signature: 3

Total no. authors: 8

Impact source: ISI

Impact index in year of publication: 5,578

Category: Science Edition - MULTIDISCIPLINARY SCIENCES

Journal in the top 25%: Yes

- 12** Esmeralda Carrillo; Saúl Abenhamar Navarro; Alberto Ramírez; María Ángel García; Carmen Griñán Lisón; Macarena Perán; Juan Antonio Marchal. 5-Fluorouracil derivatives: a patent review (2012 - 2014).Expert opinion on therapeutic patents. 25 - 10, pp. 1131 - 1175. 2015. ISSN 1744-7674

DOI: 10.1517/13543776.2015.1056736

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Category: Science Edition - MEDICINE, LEGAL

Impact index in year of publication: 4,297

Journal in the top 25%: Yes

- 13** CF de la Cruz Herrera; M Campagna; L Marcos Villar; MA Garcia; V Lang; M Baz Martinez; S Gutierrez; A Vidal; MS Rodriguez; C Rivas. Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier (SUMO).J Biol Chem. 289 - 38, pp. 26357 - 26367. 19/09/2014.

DOI: 10.1074/jbc.M114.560961

Type of production: Scientific paper

Format: Journal

Corresponding author: No

Impact source: ISI

Impact index in year of publication: 4,573

- 14** MJ Serrano; FG Ortega; MJ Alvarez Cubero; J Nadal; P Sanchez Robira; M Salido; M Rodriguez; JL Garcia Puche; M Delgado Rodriguez; F Sole; MA Garcia; M Peran; R Rossel; JA Marchal; JA Lorente. EMT and EGFR in CTCs cytokeatin negative non-metastatic breast cancer.Oncotarget. 5 - 17, pp. 7486 - 7497. 15/09/2014.

EID: 2-s2.0-84907484036

Type of production: Scientific paper

Format: Journal

Corresponding author: No

Impact source: ISI

Category: Oncology

Impact index in year of publication: 6,359

Journal in the top 25%: Yes

- 15** Elena López Ruiz; Macarena Perán; Manuel Picón Ruiz; Maria Angel García; Esmeralda Carrillo; Manuel Jiménez Navarro; M Carmen Hernández; Isidro Prat; Eduardo De Teresa; Juan Antonio Marchal. Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction.Cytotherapy. 23/06/2014. ISSN 1477-2566

DOI: 10.1016/j.jcyt.2014.05.012

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Impact index in year of publication: 3,055

Relevant results: doi: 10.1016/j.jcyt.2014.05.012 Q2

- 16** Alberto Ramírez; Houria Boulaiz; Cynthia Morata Tarifa; Macarena Perán; Gema Jiménez; Manuel Picon Ruiz; Ahmad Agil; Olga Cruz López; Ana Conejo García; Joaquín M Campos; Ana Sánchez; María A García; Juan A Marchal. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozopiniib small compound.Oncotarget. 13/05/2014. ISSN 1949-2553

EID: 2-s2.0-84907484036

Type of production: Scientific paper

Format: Journal

Corresponding author: Yes

Impact source: ISI

Category: Oncology



Impact index in year of publication: 6,636

Journal in the top 25%: Yes

Relevant results: <http://www.ncbi.nlm.nih.gov/pubmed/24946763> Q1

- 17** Macarena Perán; Juan Antonio Marchal; Maria A García; Julian Kenyon; David Tosh. In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation. Cellular oncology (Dordrecht). 36 - 4, pp. 289 - 590. 07/2013. ISSN 2211-3436
DOI: 10.1007/s13402-013-0134-8
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 2,400
Relevant results: Q2
- 18** Juan Antonio Marchal; Esther Carrasco; Alberto Ramirez; Gema Jiménez; Carmen Olmedo; Macarena Peran; Ahmad Agil; Ana Conejo García; Olga Cruz López; Joaquin María Campos; María Ángel García. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFN γ triggering apoptosis, autophagy and senescence. Drug design, development and therapy. 7, pp. 1301 - 1314. (New Zealand): 2013. ISSN 1177-8881
DOI: 10.2147/DDDT.S51354
Type of production: Scientific paper **Format:** Journal
Corresponding author: Yes
Impact source: ISI
Impact index in year of publication: 3,486
Relevant results: Q1
- 19** Yolande Asara; Juan A Marchal; Esther Carrasco; Houria Boulaiz; Giuliana Solinas; Pasquale Bandiera; Maria A Garcia; Cristiano Farace; Andrea Montella; Roberto Madeddu. Cadmium modifies the cell cycle and apoptotic profiles of human breast cancer cells treated with 5-fluorouracil. International journal of molecular sciences. 14 - 8, pp. 16600 - 16616. (Switzerland): 2013. ISSN 1422-0067
EID: 2-s2.0-84897367991
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 2,464
Relevant results: Q2
- 20** M E García Rubiño; A Conejo García; M C Núñez; E Carrasco; M A García; D Choquesillo Lazarte; J M García Ruiz; M A Gallo; J A Marchal; J M Campos. Enantiospecific synthesis of heterocycles linked to purines: different apoptosis modulation of enantiomers in breast cancer cells. Current medicinal chemistry. 20 - 38, pp. 4924 - 4958. 2013. ISSN 1875-533X
DOI: 10.2174/09298673113206660263
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 4,070
Impact source: ISI
Impact index in year of publication: 4,070
Relevant results: D1
- 21** Macarena Perán; María Angel García; Elena López Ruiz; Gema Jimenez; Juan Antonio Marchal. How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue Regeneration. Materials. 6, pp. 1333 - 1359. 2013. ISSN 1996-1944

DOI: 10.3390/ma6041333

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Impact index in year of publication: 2,247

Relevant results: Q1

- 22** Macarena Perán; María A García; Elena López Ruiz; Milán Bustamante; Gema Jiménez; Roberto Madeddu; Juan A Marchal. Functionalized nanostructures with application in regenerative medicine. *International journal of molecular sciences*. 13 - 3, pp. 3847 - 3933. (Switzerland): 2012. ISSN 1422-0067

DOI: 10.3390/ijms13033847

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Impact index in year of publication: 2,464

Relevant results: Q2

- 23** José González Santamaría; Michela Campagna; María Angel García; Laura Marcos Villar; Dolores González; Pedro Gallego; Fernando Lopitz Otsoa; Susana Guerra; Manuel S Rodríguez; Mariano Esteban; Carmen Rivas. Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. *Journal of virology*. 85 - 24, pp. 12890 - 13790. 12/2011. ISSN 1098-5514

DOI: 10.1128/JVI.05628-11

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Category: Science Edition - VIROLOGY

Impact index in year of publication: 5,076

Journal in the top 25%: Yes

Relevant results: Q1

- 24** María Kimatrai; Ana Conejo García; Alberto Ramírez; Elena Andreolli; Adriane Da Silveira Gomes; María Angel García; Antonia Aránega; Juan A Marchal; Joaquín M Campos. Synthesis and anticancer activity of the (R,S)-benzofused 1,5-oxathiepine moiety tethered to purines through alkylidenoxy linkers. *ChemMedChem*. 6 - 10, pp. 1854 - 1863. (Germany): 04/10/2011. ISSN 1860-7187

DOI: 10.1002/cmcd.201100276

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Impact index in year of publication: 2,835

Relevant results: Q2

- 25** Ana Conejo García; M Eugenia García Rubiño; Juan A Marchal; M Carmen Núñez; Alberto Ramírez; Sandro Cimino; M Ángel García; Antonia Aránega; Miguel A Gallo; Joaquín M Campos. Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2-ylmethyl)-9H-purines. *European journal of medicinal chemistry*. 46 - 9, pp. 3795 - 4596. (France): 09/2011. ISSN 1768-3254

DOI: 10.1016/j.ejmech.2011.05.046

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Impact index in year of publication: 3,499

Relevant results: Q1

- 26** Luisa C López Cara; Ana Conejo García; Juan A Marchal; Giuseppe Macchione; Olga Cruz López; Houria Boulaiz; María A García; Fernando Rodríguez Serrano; Alberto Ramírez; Carlos Cativiela; Ana I Jiménez; Juan M García Ruiz; Duane Choquesillo Lazarte; Antonia Aránega; Joaquín M Campos. New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from



(RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine. European journal of medicinal chemistry. 46 - 1, pp. 249 - 307. (France): 01/2011. ISSN 1768-3254

DOI: 10.1016/j.ejmech.2010.11.011

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Impact index in year of publication: 3,499

Relevant results: Q1

- 27** M Campagna; D Herranz; M A Garcia; L Marcos Villar; J González Santamaría; P Gallego; S Gutierrez; M Collado; M Serrano; M Esteban; C Rivas. SIRT1 stabilizes PML promoting its sumoylation. Cell death and differentiation. 18 - 1, pp. 72 - 81. 01/2011. ISSN 1476-5403

DOI: 10.1038/cdd.2010.77

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Category: Cell Biology

Impact index in year of publication: 8,371

Journal in the top 25%: Yes

Relevant results: D1

- 28** María Angel García; Esther Carrasco; Margarita Aguilera; Pablo Alvarez; Carmen Rivas; Joaquin María Campos; Jose Carlos Prados; Miguel Angel Calleja; Mariano Esteban; Juan Antonio Marchal; Antonia Aránega. The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PloS one. 6 - 8, pp. e23887. 2011. ISSN 1932-6203

DOI: 10.1371/journal.pone.0023887

Type of production: Scientific paper

Format: Journal

Corresponding author: Yes

Impact source: ISI

Category: Mol Biology

Impact index in year of publication: 3,730

Journal in the top 25%: Yes

Relevant results: Q1

- 29** MARÍA ANGEL GARCÍA; Magdalena Krupa; Mariano Esteban. Antitumoral activity of oncolytic vaccinia virus expressing the interferon induced ds-RNA dependent protein kinase PKR. Anales de la Real Academia Nacional de Farmacia. 76 - 3, pp. 327 - 342. 2010.

Type of production: Scientific paper

Format: Journal

- 30** Maria A Garcia; Pedro Gallego; Michela Campagna; José González Santamaría; Gloria Martínez; Laura Marcos Villar; Anxo Vidal; Mariano Esteban; Carmen Rivas. Activation of NF- κ B pathway by virus infection requires Rb expression. PloS one. 4 - 7, pp. e6422. 2009. ISSN 1932-6203

DOI: 10.1371/journal.pone.0006422

Type of production: Scientific paper

Impact source: ISI

Category: Molecular Biology

Impact index in year of publication: 3,730

Journal in the top 25%: Yes

Relevant results: Q1

- 31** María A García; Manuel Collado; César Muñoz Fontela; Ander Matheu; Laura Marcos Villar; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas. Antiviral action of the tumor suppressor ARF. The EMBO journal. 25 - 18, pp. 4284 - 4376. 20/09/2006. ISSN 0261-4189

DOI: 10.1038/sj.emboj.7601302

Type of production: Scientific paper

Format: Journal

Impact source: ISI

Category: Molecular Biology

Impact index in year of publication: 10,748

Journal in the top 25%: Yes



- 32** Susana Guerra; Luis A López Fernández; María Angel García; Angel Zaballos; Mariano Esteban. Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. The Journal of biological chemistry. 281 - 27, pp. 18734 - 18779. 07/07/2006. ISSN 0021-9258
DOI: 10.1074/jbc.M511983200
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Cell Biology
Impact index in year of publication: 4,573 **Journal in the top 25%:** Yes
- 33** C Muñoz Fontela; M Collado; E Rodriguez; M A García; A Alvarez Barrientos; J Arroyo; C Nombela; C Rivas. Identification of a nuclear export signal in the KSHV latent protein LANA2 mediating its export from the nucleus. Experimental cell research. 311 - 1, pp. 96 - 201. 15/11/2005. ISSN 0014-4827
DOI: 10.1016/j.yexcr.2005.08.022
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 3,246
- 34** Cesar Munoz Fontela; Maria Angel Garcia; Isabel Garcia Cao; Manuel Collado; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas. Resistance to viral infection of super p53 mice. Oncogene. 24 - 18, pp. 3059 - 3121. 21/04/2005. ISSN 0950-9232
DOI: 10.1038/sj.onc.1208477
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 8,459 **Journal in the top 25%:** Yes
- 35** Carmen E Gómez; Andrée Marie Vandermeeren; María Angel García; Elena Domingo Gil; Mariano Esteban. Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant. Virology journal. 2, pp. 81. 2005. ISSN 1743-422X
DOI: 10.1186/1743-422X-2-81
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Science Edition - VIROLOGY
Impact index in year of publication: 5,734 **Journal in the top 25%:** Yes
- 36** Jesús Gil; Maria Angel García; Paulino Gomez Puertas; Susana Guerra; Joaquín Rullas; Hiroyasu Nakano; José Alcamí; Mariano Esteban. TRAF family proteins link PKR with NF-kappa B activation. Molecular and cellular biology. 24 - 10, pp. 4502 - 4514. 05/2004. ISSN 0270-7306
DOI: C10.1186/1743-422X-2-81
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Cell Biology
Impact index in year of publication: 4,777 **Journal in the top 25%:** Yes
- 37** M Esteban; M A García; E Domingo Gil; J Arroyo; C Nombela; C Rivas. The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. The Journal of general virology. 84 - Pt 6, pp. 1463 - 1533. 06/2003. ISSN 0022-1317
DOI: 10.1099/vir.0.19014-0
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 3,230



- 38** Maria Angel García; Susana Guerra; Jesús Gil; Victoria Jimenez; Mariano Esteban. Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. *Oncogene*. 21 - 55, pp. 8379 - 8466. 05/12/2002. ISSN 0950-9232
DOI: 10.1038/sj.onc.1206036
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 8,459 **Journal in the top 25%:** Yes
- 39** Jesús Gil; Maria Angel García; Mariano Esteban. Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. *FEBS letters*. 529 - 2-3, pp. 249 - 304. 09/10/2002. ISSN 0014-5793
DOI: 10.1016/S0014-5793(02)03348-3
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 3,169
- 40** J Gil; J Rullas; M A García; J Alcamí; M Esteban. The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation. *Oncogene*. 20 - 3, pp. 385 - 479. 18/01/2001. ISSN 0950-9232
DOI: 10.1038/sj.onc.1204109
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 8,459 **Journal in the top 25%:** Yes
- 41** Laura García-Hernandez; Maria Belen García-Ortega; Gloria Ruiz; Juan Antonio Marchal; María Angel García. The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer. *Int J Mol Sci*. 23 - 1, pp. 370. MDPI, 29/12/2021.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 42** Pablo Hernández-Camarero; Victor Amexcua-Hernandez; Gema Jimenez; Maria Angel Garcia; Macarena Peran. Clinical failure of nanoparticles in cancer: Mimicking nature's solutions. *Nanomedicine*. 15 - 23, pp. 2311 - 2324. *Future Medicine*, 01/08/2020.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: No
- 43** Guilherme Ribeiro Romualdo; Ariane Bartolomeu Rocha; Mathieu Vinken; Bruno Cogliati; Fernando Salvador Moreno; María Angel García Chaves; Luis Fernando Barbisan. Drinking for protection? Epidemiological and experimental evidence on the beneficial effects of coffee or major coffee compounds against gastrointestinal and liver carcinogenesis. *Food research international (Ottawa, Ont.)*. 123, pp. 567 - 589. (Canada): 09/2019. ISSN 1873-7145
DOI: 10.1016/j.foodres.2019.05.029
Type of production: Bibliographic review
Position of signature: 6
Total no. authors: 7
- 44** Garcia-Ortega MB; Lopez GJ; Jimenez G; Garcia-Garcia JA; Conde V; Boulaiz H; Perán M; Marchal JA; Carrillo E; Garcia MA. Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism. *Expert Reviews in Molecular Medicine*. 19 - e9, pp. 1 - 13. 2017.
DOI: 10.1017/erm.2017.11
Type of production: Bibliographic review **Format:** Journal

Position of signature: 10
Total no. authors: 10

Corresponding author: Yes

- 45** A historical overview of protein kinase PKR: from its discovery and mechanism of action to its clinical and therapeutic implications. *Anales de la Real Academia Nacional de Farmacia*. 82 - 2, pp. 143 - 167. 01/06/2016.

Type of production: Bibliographic review

Format: Journal

Position of signature: 1

Total no. authors: 1

Corresponding author: Yes

- 46** Elena Lopez Ruiz; Gema Jimenez; Maria Angel Garcia; Cristina Antich; Houria Boulaiz; Juan Antonio Marchal; Macarena Peran. Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new?. *Expert Opin Ther Pat*. 26 - 8, pp. 877 - 890. 2016.

DOI: 10.1080/13543776.2016.1203903

Type of production: Bibliographic review

Format: Journal

Position of signature: 3

Total no. authors: 7

Corresponding author: No

- 47** Juan A Marchal; Gabriel J Lopez; Macarena Peran; Ana Comino; Juan R Delgado; Javier A García García; Veronica Conde; Fernando M Aranda; Carmen Rivas; Mariano Esteban; Maria A Garcia. The impact of PKR activation: from neurodegeneration to cancer. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 28 - 5, pp. 1965 - 2039. 05/2014. ISSN 1530-6860

DOI: 10.1096/fj.13-248294

Type of production: Bibliographic review

Format: Journal

Corresponding author: Yes

Impact source: ISI

Category: Cell Biology

Impact index in year of publication: 5,704

Journal in the top 25%: Yes

Relevant results: D1

- 48** César Muñoz Fontela; María A García; Manuel Collado; Laura Marcos Villar; Pedro Gallego; Mariano Esteban; Carmen Rivas. Control of virus infection by tumour suppressors. *Carcinogenesis*. 28 - 6, pp. 1140 - 1144. 06/2007. ISSN 0143-3334

DOI: 10.1093/carcin/bgm048

Type of production: Bibliographic review

Format: Journal

Impact source: ISI

Category: Oncology

Impact index in year of publication: 5,334

Journal in the top 25%: Yes

- 49** MARÍA ANGEL GARCÍA; C Muñoz Fontela; Manuel Collado; Laura Marcos Villar; Mariano Esteban; Carmen Rivas. A novel and unexpected role for the tumor suppressor ARF in viral infection surveillance. *Future Virology*. 2 - 6, pp. 625 - 629. 2007.

DOI: 10.2217/17460794.2.6.625

Type of production: Bibliographic review

Format: Journal

- 50** M A García; E F Meurs; M Esteban. The dsRNA protein kinase PKR: virus and cell control. *Biochimie*. 89 - 6-7, pp. 799 - 1610. (France): 2007. ISSN 0300-9084

Type of production: Bibliographic review

Format: Journal

Impact source: ISI

Impact index in year of publication: 3,123



- 51** M A García; J Gil; I Ventoso; S Guerra; E Domingo; C Rivas; M Esteban. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. *Microbiology and molecular biology reviews* : MMBR. 70 - 4, pp. 1032 - 1092. 12/2006. ISSN 1092-2172
DOI: 10.1128/MMBR.00027-06
Type of production: Bibliographic review
Impact source: ISI
Impact index in year of publication: 14,6
- Format:** Journal
Category: Science Edition - BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Journal in the top 25%: Yes

Works submitted to national or international conferences

- 1** **Title of the work:** Interferon-alpha decreases Cancer Stem Cells in Malignant Melanoma.
Name of the conference: 42 Congreso de la Sociedad Española de Bioquímica y Biología Molecular,
Corresponding author: Yes
City of event: Madrid,
Date of event: 2019
Organising entity: Sociedad Española de Bioquímica
- 2** **Title of the work:** Metabolomics Characterization Of Exosomes Derived From Melanoma Cancer Stem Cells
Name of the conference: II National Congress of Young Researchers in Biomedicine
City of event: Valencia,
Date of event: 2017
- 3** **Title of the work:** Metabolomics Characterization of Exosomes Derived from Melanoma Cancer Stem Cell
Name of the conference: Select Biosciences Extracellular Vesicles
City of event: Cambridge, United Kingdom
Date of event: 2017
- 4** **Title of the work:** Microrna/Exosomas Característicos De Células Madre Cancerígenas (CSCs) Con Valor Pronóstico y Predictivo de Respuesta a Terapias Combinadas con Pacientes con melanoma Maligno y Cáncer de Colon
Name of the conference: II Jornadas de Investigadores en formación de la Universidad de Granada
Date of event: 2017
Organising entity: Universidad de Granada
Type of entity: University
- 5** **Title of the work:** SIDT1 is a key player for IFN responses in human pDC
Name of the conference: XXXVIII Congreso Nacional de Inmunología
City of event: Badajoz, Extremadura, Spain
Date of event: 08/05/2014
Organising entity: Sociedad Española de Inmunología
C Coppard; N Castillejo López; N Varela; María Angel García; Marta Alarcon; Concepción Marañón.
- 6** **Title of the work:** IDENTIFICATION OF INTERFERON-INDUCED PKR PROTEIN AS A KEY MOLECULAR TARGET OF THE CHEMOTHERAPEUTIC DRUG 5-FLUOROURACIL
Name of the conference: CYTOKINES AND INTERFERON:FROM THE BENCH TO THE BEDSIDE
Geographical area: Non EU International
City of event: FIRENZE, Italy
Date of event: 12/09/2011



Organising entity: INTERNATIONAL CYTOKINE SOCIETY AND INTERNATIONAL SOCIETY FOR INTERFERON AND CYTOKINE RESEARCH

María Angel García; Esther Carrasco; Margarita Aguilera; Pablo Alvarez; Carmen Rivas; Joaquin M Campos; Miguel Angel Calleja; Mariano Esteban; Juan Antonio Marchal; Antonia Aranega. 56 - 1, pp. 41. ISSN 1043-4666

7 Title of the work: INTERFERON ALPHA ENHANCES THE ANTITUMOR ACTIVITY OF A NOVEL PURINE DERIVATE DRUG

Name of the conference: CYTOKINES AND INTERFERON:FROM THE BENCH TO THE BEDSIDE

Geographical area: Non EU International

City of event: FIRENZE, Italy

Date of event: 12/09/2011

Organising entity: INTERNATIONAL CYTOKINE SOCIETY AND INTERNATIONAL SOCIETY FOR INTERFERON AND CYTOKINE RESEARCH

Juan Antonio Marchal; María Angel García; Alberto Ramirez; Esther Carrasco; Houria Boulaiz; Gema Jimenez; Ana Conejo; Pablo Alvarez; Antonia Aranega. 56 - 1, pp. 96. ISSN 1043-4666

8 Title of the work: DIFERENCIACION CONDROCITICA INDUCIDA POR SOX9EN CELULAS MADRE MESENQUIMALES AISLADASDE LA GRASA INFRAPATELARDE PACIENTES CON OSTEOARTRITIS

Name of the conference: JORNADAS ANDALUZAS SALUD INVESTIGA

City of event: Cádiz, Andalusia, Spain

Date of event: 20/10/2010

Organising entity: FUNDACION PROGRESO Y SALUD

Elena Lopez; Juan Antonio Marchal; Macarena Peran; Esther Carrasco; Houria Boulaiz; Maria Angel Garcia; Fernando Rodriguez; Esmeralda Carrillo; Ana Conejo; Joaquin M Campos; Antonia Aranega.

9 Title of the work: PURIFICACION Y EXPANSION DE CELULAS MULTIPOTENTESDE TIPO ENDOTELIAL DE LIPOASPIRADOSCON POTENCIAL

Name of the conference: JORNADAS ANDALUZAS SALUD INVESTIGA

City of event: Cádiz, Andalusia, Spain

Date of event: 20/10/2010

Organising entity: FUNDACION PROGRESO Y SALUD

Juan Antonio Marchal; Esther Carrasco; Houria Boulaiz; Fernando Rodriguez; Macarena Peran; Maria Angel Garcia; Esmeralda Carrillo; Ana Conejo; Joaquin M Campos; Antonia Aranega.

10 Title of the work: REGULACION DEL CICLO CELULAR E INDUCCION DE APOPTOSIS PRODUCIDA POR COMPUESTOS DERIVADOS DEL URACILOCON ACTIVIDAD ANTUTUMORAL SELECTIVAFRENTE A CELULAS TUMORALES DE MAMA

Name of the conference: JORNADAS ANDALUZAS SALUD INVESTIGA

City of event: Cádiz, Andalusia, Spain

Date of event: 20/10/2010

Organising entity: FUNDACION PROGRESO Y SALUD

Maria Angel Garcia; Juan Antonio Marchal; Esther Carrasco; Houria Boulaiz; Fernando Rodriguez; Macarena Peran; Esmeralda Carrillo; Ana Conejo; Joaquin M Campos; Antonia Aranega.

11 Title of the work: SUMO regulation of Vaccinia virus E3L protein.

Name of the conference: XVIII International poxvirus, asfvirus, and ridoivirus symposium

City of event: Arizona, United States of America

Date of event: 10/10/2010

Organising entity: Sociedad Nacional de Virología

Michela Campagna; Laura Marcos Villar; Maria Angel García; David González; Mariano Esteban; Carmen Rivas.